Search results
Results from the WOW.Com Content Network
The study found a 39% lower HIV infection rate in women using 1% tenofovir gel compared with women using a placebo gel. In addition, tenofovir gel was shown to be safe as tested. [ 21 ] The results of the CAPRISA 004 trial provide statistically significant evidence that ARVs, topically applied to the vaginal mucosa, can offer protection against ...
HIV/AIDS was first detected in Canada in 1982. [1] [2] In 2018, there were approximately 62,050 people living with HIV/AIDS in Canada. [3] It was estimated that 8,300 people were living with undiagnosed HIV in 2018. [3] Mortality has decreased due to medical advances against HIV/AIDS, especially highly active antiretroviral therapy (HAART).
As of December 1989, around 1,250 Canadians, many of them hemophiliacs, were known to have contracted HIV through blood products. [1] Once the extent of the infection of the tragedy was known, the Red Cross failed to track down those who had received tainted blood so that they could receive treatment and avoid passing on the viruses to others. [6]
Gilead Sciences, Inc. (/ ˈ ɡ ɪ l i ə d /) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Dolutegravir (DTG), sold under the brand name Tivicay, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. [6] It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. [7] It is taken by mouth. [6]
Canadian Foundation for AIDS Research (CANFAR) was created in 1987 by four friends (Dinah Koo, Van Beltreme, Jack Creed and Robert Mang) in an effort to support HIV/AIDS research that would lead to a cure since Canada's emerging HIV/AIDS organizations primarily dealt with the, just as significant, need to care and support people living with the disease.
"HIV is now a chronic disease, and what matters is viral load — and we can get that viral load to zero," he went on. "Giving HIV positive organs to HIV positive recipients makes total sense ...
Rilpivirine, sold under the brand names Edurant and Rekambys, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. [5] [6] It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs such as efavirenz.